
S&P TEST

SWOT & PESTLE.com

BRISTOL-MYERS SQUIBB (BMS) SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. To purchase reprints of this document, please email support@swotandpestle.com.

Company Name : Bristol-Myers Squibb (BMS)

Company Sector : Pharmaceuticals

Operating Geography : United States, North America, Global

About the Company :

Bristol-Myers Squibb (BMS) is an American pharmaceutical company, headquartered in New York City. Their products are sold worldwide (U.S. being the biggest market, contributing 63% to overall revenue) and manufactured in the U.S., Puerto Rico and in five foreign countries. BMS was formed by the 1989 merger of Squibb (founded in 1858 in Brooklyn) and Bristol-Myers (founded in 1887 in Clinton, New York). Their Products can be categorized in the following major therapeutic classes: oncology; cardiovascular; immune-science; and virology, including HIV infection. As of 2021, it employees 32,200 people globally. Bristol Myers Squibb has been named a U.S. EPA Energy Star Partner of the Year (ESPOY) for the eighth consecutive year, receiving the Sustained Excellence designation for the past four years. A definitive merger agreement between Bristol Myers Squibb and Turning Point Therapeutics, Inc. was announced in March 2022. Bristol Myers Squibb will buy Turning Point Therapeutics for \$76.00 per share. The deal is expected to be finalised in the third quarter of 2022. With the help of this deal, Bristol will be able to maximise the capabilities of its precision oncology platform and raise the bar for cancer patients' care.

The USP of Bristol lies is that it is one of the world's largest pharmaceutical companies. Bristol mission statement states 'To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.' While vision is "To be the world's leading biopharma company that transforms patients' lives through science".

Revenue :

\$46.4 billion – FY ending 31st Dec 2021 (y-o-y growth 9%)

\$42.5 billion – FY ending 31st Dec 2020

SWOT Analysis :

The SWOT Analysis for Bristol-Myers Squibb (BMS) is given below:

Strengths	Weaknesses
<ul style="list-style-type: none"> 1. Innovation \u2013 New Product Development 2. Strong focus on Research and Development 3. Strong and diverse brand portfolio 4. High credit rating, low borrowing cost 5. Complimentary alliances for vertical integration 6. Breakthrough solutions developed for diseases 	<ul style="list-style-type: none"> 1. Revenue dependence on few prioritized brands 2. Weak presence in biologics segment 3. Major dependency on US and European markets 4. Loss of market exclusivity of the products
Opportunities	Threats
<ul style="list-style-type: none"> 1. Growing cancer immunotherapy market 2. Increasing globalization in Pharma industry, opening of new markets through trade agreements 3. Leverage advance digital technologies to transform healthcare 	<ul style="list-style-type: none"> 1. Increasing competition from generic drugs manufacturers 2. Changes in U.S. or foreign laws and regulations 3. Adverse changes in U.S., global, regional or local economic conditions

PESTLE Analysis :

The PESTLE Analysis for Bristol-Myers Squibb (BMS) is given below:

<p style="text-align: center;">Political</p> <p>1.Impact of U.S. \u2013 China trade war on pharma</p>	<p style="text-align: center;">Economical</p> <p>1.Fluctuations in currency market 2.Impact of global economic uncertainty</p>
<p style="text-align: center;">Social</p> <p>1.Continued aging of the global population 2.Increase in lifestyle-related diseases</p>	<p style="text-align: center;">Technological</p> <p>1.Proliferation in digital health technologies 2.Rise in advanced analytics 3.Integration of automation and virtual reality in manufacturing plants</p>
<p style="text-align: center;">Legal</p> <p>1.Changes in IP protection laws 2.Laws to reduce circulation of counterfeit drugs</p>	<p style="text-align: center;">Environmental</p> <p>1.Corporate vision aligned with sustainable development to address climate change</p>

Please note that our free summary reports contain the SWOT and PESTLE table contents only. The complete report for **Bristol-Myers Squibb (BMS)** SWOT & PESTLE Analysis is a paid report at **15.53 U.S.D.**



* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:
support@swotandpestle.com